Pharma & Healthcare
Global Human Immunodeficiency Virus Type-1 Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 04, 25
- ID: 533847
- Pages: 127
- Figures: 130
- Views: 3
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Human Immunodeficiency Virus Type-1 market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche
Bristol Myers Squibb
Merck & Co. Inc.
GSK
Pfizer
Viatris
Sanofi
AstraZeneca
Novartis
Bayer
Segment by Type
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitors (PIs)
Integrase Inhibitor
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Human Immunodeficiency Virus Type-1 study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Human Immunodeficiency Virus Type-1 market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche
Bristol Myers Squibb
Merck & Co. Inc.
GSK
Pfizer
Viatris
Sanofi
AstraZeneca
Novartis
Bayer
Segment by Type
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitors (PIs)
Integrase Inhibitor
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Human Immunodeficiency Virus Type-1 study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Human Immunodeficiency Virus Type-1: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Human Immunodeficiency Virus Type-1 Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Protease Inhibitors (PIs)
1.2.5 Integrase Inhibitor
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Human Immunodeficiency Virus Type-1 Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Immunodeficiency Virus Type-1 Revenue Estimates and Forecasts 2020-2031
2.2 Global Human Immunodeficiency Virus Type-1 Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Human Immunodeficiency Virus Type-1 Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Human Immunodeficiency Virus Type-1 Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Size by Players
3.3.2 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Market Size by Players
3.3.3 Protease Inhibitors (PIs) Market Size by Players
3.3.4 Integrase Inhibitor Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Human Immunodeficiency Virus Type-1 Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Human Immunodeficiency Virus Type-1 Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Human Immunodeficiency Virus Type-1 Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
6.4 North America Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Human Immunodeficiency Virus Type-1 Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
7.4 Europe Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Human Immunodeficiency Virus Type-1 Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
8.4 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
9.4 Central and South America Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Human Immunodeficiency Virus Type-1 Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
10.4 Middle East and Africa Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Human Immunodeficiency Virus Type-1 Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.1.4 Roche Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.1.5 Roche Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.1.6 Roche Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.1.7 Roche Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.1.8 Roche Human Immunodeficiency Virus Type-1 SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Corporation Information
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.2.4 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.2.5 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.2.6 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.2.7 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.2.8 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 SWOT Analysis
11.2.9 Bristol Myers Squibb Recent Developments
11.3 Merck & Co. Inc.
11.3.1 Merck & Co. Inc. Corporation Information
11.3.2 Merck & Co. Inc. Business Overview
11.3.3 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.3.4 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.3.5 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.3.6 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.3.7 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.3.8 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 SWOT Analysis
11.3.9 Merck & Co. Inc. Recent Developments
11.4 GSK
11.4.1 GSK Corporation Information
11.4.2 GSK Business Overview
11.4.3 GSK Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.4.4 GSK Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.4.5 GSK Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.4.6 GSK Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.4.7 GSK Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.4.8 GSK Human Immunodeficiency Virus Type-1 SWOT Analysis
11.4.9 GSK Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.5.4 Pfizer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.5.6 Pfizer Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.5.7 Pfizer Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.5.8 Pfizer Human Immunodeficiency Virus Type-1 SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Viatris
11.6.1 Viatris Corporation Information
11.6.2 Viatris Business Overview
11.6.3 Viatris Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.6.4 Viatris Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.6.5 Viatris Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.7.4 Sanofi Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.7.5 Sanofi Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Corporation Information
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.8.4 AstraZeneca Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.8.5 AstraZeneca Recent Developments
11.9 Novartis
11.9.1 Novartis Corporation Information
11.9.2 Novartis Business Overview
11.9.3 Novartis Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.9.4 Novartis Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.9.5 Novartis Recent Developments
11.10 Bayer
11.10.1 Bayer Corporation Information
11.10.2 Bayer Business Overview
11.10.3 Bayer Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.10.4 Bayer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Human Immunodeficiency Virus Type-1Industry Chain Analysis
12.1 Human Immunodeficiency Virus Type-1 Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Human Immunodeficiency Virus Type-1 Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Human Immunodeficiency Virus Type-1 Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Human Immunodeficiency Virus Type-1: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Human Immunodeficiency Virus Type-1 Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Protease Inhibitors (PIs)
1.2.5 Integrase Inhibitor
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Human Immunodeficiency Virus Type-1 Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Immunodeficiency Virus Type-1 Revenue Estimates and Forecasts 2020-2031
2.2 Global Human Immunodeficiency Virus Type-1 Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Human Immunodeficiency Virus Type-1 Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Human Immunodeficiency Virus Type-1 Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Market Size by Players
3.3.2 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Market Size by Players
3.3.3 Protease Inhibitors (PIs) Market Size by Players
3.3.4 Integrase Inhibitor Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Human Immunodeficiency Virus Type-1 Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Human Immunodeficiency Virus Type-1 Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Human Immunodeficiency Virus Type-1 Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
6.4 North America Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Human Immunodeficiency Virus Type-1 Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
7.4 Europe Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Human Immunodeficiency Virus Type-1 Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
8.4 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
9.4 Central and South America Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Human Immunodeficiency Virus Type-1 Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Human Immunodeficiency Virus Type-1 Market Size by Type (2020-2031)
10.4 Middle East and Africa Human Immunodeficiency Virus Type-1 Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Human Immunodeficiency Virus Type-1 Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.1.4 Roche Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.1.5 Roche Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.1.6 Roche Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.1.7 Roche Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.1.8 Roche Human Immunodeficiency Virus Type-1 SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Corporation Information
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.2.4 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.2.5 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.2.6 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.2.7 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.2.8 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 SWOT Analysis
11.2.9 Bristol Myers Squibb Recent Developments
11.3 Merck & Co. Inc.
11.3.1 Merck & Co. Inc. Corporation Information
11.3.2 Merck & Co. Inc. Business Overview
11.3.3 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.3.4 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.3.5 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.3.6 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.3.7 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.3.8 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 SWOT Analysis
11.3.9 Merck & Co. Inc. Recent Developments
11.4 GSK
11.4.1 GSK Corporation Information
11.4.2 GSK Business Overview
11.4.3 GSK Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.4.4 GSK Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.4.5 GSK Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.4.6 GSK Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.4.7 GSK Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.4.8 GSK Human Immunodeficiency Virus Type-1 SWOT Analysis
11.4.9 GSK Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.5.4 Pfizer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Human Immunodeficiency Virus Type-1 Revenue by Product in 2024
11.5.6 Pfizer Human Immunodeficiency Virus Type-1 Revenue by Application in 2024
11.5.7 Pfizer Human Immunodeficiency Virus Type-1 Revenue by Geographic Area in 2024
11.5.8 Pfizer Human Immunodeficiency Virus Type-1 SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Viatris
11.6.1 Viatris Corporation Information
11.6.2 Viatris Business Overview
11.6.3 Viatris Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.6.4 Viatris Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.6.5 Viatris Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.7.4 Sanofi Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.7.5 Sanofi Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Corporation Information
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.8.4 AstraZeneca Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.8.5 AstraZeneca Recent Developments
11.9 Novartis
11.9.1 Novartis Corporation Information
11.9.2 Novartis Business Overview
11.9.3 Novartis Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.9.4 Novartis Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.9.5 Novartis Recent Developments
11.10 Bayer
11.10.1 Bayer Corporation Information
11.10.2 Bayer Business Overview
11.10.3 Bayer Human Immunodeficiency Virus Type-1 Product Features and Attributes
11.10.4 Bayer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Human Immunodeficiency Virus Type-1Industry Chain Analysis
12.1 Human Immunodeficiency Virus Type-1 Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Human Immunodeficiency Virus Type-1 Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Human Immunodeficiency Virus Type-1 Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Human Immunodeficiency Virus Type-1 Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Human Immunodeficiency Virus Type-1 Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Human Immunodeficiency Virus Type-1 Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Human Immunodeficiency Virus Type-1 by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunodeficiency Virus Type-1 as of 2024)
Table 11. Global Human Immunodeficiency Virus Type-1 Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Human Immunodeficiency Virus Type-1 Companies Headquarters
Table 13. Global Human Immunodeficiency Virus Type-1 Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2026-2031) & (US$ Million)
Table 21. Human Immunodeficiency Virus Type-1 High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Human Immunodeficiency Virus Type-1 Growth Accelerators and Market Barriers
Table 25. North America Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Human Immunodeficiency Virus Type-1 Growth Accelerators and Market Barriers
Table 27. Europe Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Human Immunodeficiency Virus Type-1 Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Human Immunodeficiency Virus Type-1 Investment Opportunities and Key Challenges
Table 31. Central and South America Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Human Immunodeficiency Virus Type-1 Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Bristol Myers Squibb Corporation Information
Table 44. Bristol Myers Squibb Description and Major Businesses
Table 45. Bristol Myers Squibb Product Features and Attributes
Table 46. Bristol Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Bristol Myers Squibb Revenue Proportion by Product in 2024
Table 48. Bristol Myers Squibb Revenue Proportion by Application in 2024
Table 49. Bristol Myers Squibb Revenue Proportion by Geographic Area in 2024
Table 50. Bristol Myers Squibb Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 51. Bristol Myers Squibb Recent Developments
Table 52. Merck & Co. Inc. Corporation Information
Table 53. Merck & Co. Inc. Description and Major Businesses
Table 54. Merck & Co. Inc. Product Features and Attributes
Table 55. Merck & Co. Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Merck & Co. Inc. Revenue Proportion by Product in 2024
Table 57. Merck & Co. Inc. Revenue Proportion by Application in 2024
Table 58. Merck & Co. Inc. Revenue Proportion by Geographic Area in 2024
Table 59. Merck & Co. Inc. Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 60. Merck & Co. Inc. Recent Developments
Table 61. GSK Corporation Information
Table 62. GSK Description and Major Businesses
Table 63. GSK Product Features and Attributes
Table 64. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. GSK Revenue Proportion by Product in 2024
Table 66. GSK Revenue Proportion by Application in 2024
Table 67. GSK Revenue Proportion by Geographic Area in 2024
Table 68. GSK Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 69. GSK Recent Developments
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Major Businesses
Table 72. Pfizer Product Features and Attributes
Table 73. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Pfizer Revenue Proportion by Product in 2024
Table 75. Pfizer Revenue Proportion by Application in 2024
Table 76. Pfizer Revenue Proportion by Geographic Area in 2024
Table 77. Pfizer Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 78. Pfizer Recent Developments
Table 79. Viatris Corporation Information
Table 80. Viatris Description and Major Businesses
Table 81. Viatris Product Features and Attributes
Table 82. Viatris Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Viatris Recent Developments
Table 84. Sanofi Corporation Information
Table 85. Sanofi Description and Major Businesses
Table 86. Sanofi Product Features and Attributes
Table 87. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Sanofi Recent Developments
Table 89. AstraZeneca Corporation Information
Table 90. AstraZeneca Description and Major Businesses
Table 91. AstraZeneca Product Features and Attributes
Table 92. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. AstraZeneca Recent Developments
Table 94. Novartis Corporation Information
Table 95. Novartis Description and Major Businesses
Table 96. Novartis Product Features and Attributes
Table 97. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Novartis Recent Developments
Table 99. Bayer Corporation Information
Table 100. Bayer Description and Major Businesses
Table 101. Bayer Product Features and Attributes
Table 102. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Bayer Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Immunodeficiency Virus Type-1 Product Picture
Figure 2. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Product Picture
Figure 4. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Product Picture
Figure 5. Protease Inhibitors (PIs) Product Picture
Figure 6. Integrase Inhibitor Product Picture
Figure 7. Others Product Picture
Figure 8. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Human Immunodeficiency Virus Type-1 Report Years Considered
Figure 12. Global Human Immunodeficiency Virus Type-1 Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 14. Global Human Immunodeficiency Virus Type-1 Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Region (2020-2031)
Figure 16. Global Human Immunodeficiency Virus Type-1 Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Revenue Market Share by Player in 2024
Figure 19. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Revenue Market Share by Player in 2024
Figure 20. Protease Inhibitors (PIs) Revenue Market Share by Player in 2024
Figure 21. Integrase Inhibitor Revenue Market Share by Player in 2024
Figure 22. Others Revenue Market Share by Player in 2024
Figure 23. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Type (2020-2031)
Figure 24. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2020-2031)
Figure 25. North America Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 27. North America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 34. Europe Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 37. France Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 49. India Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 57. Central and South America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 63. South America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 69. Human Immunodeficiency Virus Type-1 Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Table 1. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Human Immunodeficiency Virus Type-1 Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Human Immunodeficiency Virus Type-1 Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Human Immunodeficiency Virus Type-1 Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Human Immunodeficiency Virus Type-1 by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunodeficiency Virus Type-1 as of 2024)
Table 11. Global Human Immunodeficiency Virus Type-1 Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Human Immunodeficiency Virus Type-1 Companies Headquarters
Table 13. Global Human Immunodeficiency Virus Type-1 Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Human Immunodeficiency Virus Type-1 Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Human Immunodeficiency Virus Type-1 Revenue by Application (2026-2031) & (US$ Million)
Table 21. Human Immunodeficiency Virus Type-1 High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Human Immunodeficiency Virus Type-1 Growth Accelerators and Market Barriers
Table 25. North America Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Human Immunodeficiency Virus Type-1 Growth Accelerators and Market Barriers
Table 27. Europe Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Human Immunodeficiency Virus Type-1 Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Human Immunodeficiency Virus Type-1 Investment Opportunities and Key Challenges
Table 31. Central and South America Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Human Immunodeficiency Virus Type-1 Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Human Immunodeficiency Virus Type-1 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Bristol Myers Squibb Corporation Information
Table 44. Bristol Myers Squibb Description and Major Businesses
Table 45. Bristol Myers Squibb Product Features and Attributes
Table 46. Bristol Myers Squibb Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Bristol Myers Squibb Revenue Proportion by Product in 2024
Table 48. Bristol Myers Squibb Revenue Proportion by Application in 2024
Table 49. Bristol Myers Squibb Revenue Proportion by Geographic Area in 2024
Table 50. Bristol Myers Squibb Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 51. Bristol Myers Squibb Recent Developments
Table 52. Merck & Co. Inc. Corporation Information
Table 53. Merck & Co. Inc. Description and Major Businesses
Table 54. Merck & Co. Inc. Product Features and Attributes
Table 55. Merck & Co. Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Merck & Co. Inc. Revenue Proportion by Product in 2024
Table 57. Merck & Co. Inc. Revenue Proportion by Application in 2024
Table 58. Merck & Co. Inc. Revenue Proportion by Geographic Area in 2024
Table 59. Merck & Co. Inc. Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 60. Merck & Co. Inc. Recent Developments
Table 61. GSK Corporation Information
Table 62. GSK Description and Major Businesses
Table 63. GSK Product Features and Attributes
Table 64. GSK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. GSK Revenue Proportion by Product in 2024
Table 66. GSK Revenue Proportion by Application in 2024
Table 67. GSK Revenue Proportion by Geographic Area in 2024
Table 68. GSK Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 69. GSK Recent Developments
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Major Businesses
Table 72. Pfizer Product Features and Attributes
Table 73. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Pfizer Revenue Proportion by Product in 2024
Table 75. Pfizer Revenue Proportion by Application in 2024
Table 76. Pfizer Revenue Proportion by Geographic Area in 2024
Table 77. Pfizer Human Immunodeficiency Virus Type-1 SWOT Analysis
Table 78. Pfizer Recent Developments
Table 79. Viatris Corporation Information
Table 80. Viatris Description and Major Businesses
Table 81. Viatris Product Features and Attributes
Table 82. Viatris Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Viatris Recent Developments
Table 84. Sanofi Corporation Information
Table 85. Sanofi Description and Major Businesses
Table 86. Sanofi Product Features and Attributes
Table 87. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Sanofi Recent Developments
Table 89. AstraZeneca Corporation Information
Table 90. AstraZeneca Description and Major Businesses
Table 91. AstraZeneca Product Features and Attributes
Table 92. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. AstraZeneca Recent Developments
Table 94. Novartis Corporation Information
Table 95. Novartis Description and Major Businesses
Table 96. Novartis Product Features and Attributes
Table 97. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Novartis Recent Developments
Table 99. Bayer Corporation Information
Table 100. Bayer Description and Major Businesses
Table 101. Bayer Product Features and Attributes
Table 102. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Bayer Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Immunodeficiency Virus Type-1 Product Picture
Figure 2. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Product Picture
Figure 4. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Product Picture
Figure 5. Protease Inhibitors (PIs) Product Picture
Figure 6. Integrase Inhibitor Product Picture
Figure 7. Others Product Picture
Figure 8. Global Human Immunodeficiency Virus Type-1 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Human Immunodeficiency Virus Type-1 Report Years Considered
Figure 12. Global Human Immunodeficiency Virus Type-1 Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 14. Global Human Immunodeficiency Virus Type-1 Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Region (2020-2031)
Figure 16. Global Human Immunodeficiency Virus Type-1 Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Revenue Market Share by Player in 2024
Figure 19. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Revenue Market Share by Player in 2024
Figure 20. Protease Inhibitors (PIs) Revenue Market Share by Player in 2024
Figure 21. Integrase Inhibitor Revenue Market Share by Player in 2024
Figure 22. Others Revenue Market Share by Player in 2024
Figure 23. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Type (2020-2031)
Figure 24. Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Application (2020-2031)
Figure 25. North America Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 27. North America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 34. Europe Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 37. France Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 49. India Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Human Immunodeficiency Virus Type-1 Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 57. Central and South America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Human Immunodeficiency Virus Type-1 Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Human Immunodeficiency Virus Type-1 Revenue (US$ Million) in 2024
Figure 63. South America Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Human Immunodeficiency Virus Type-1 Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Human Immunodeficiency Virus Type-1 Revenue (2020-2025) & (US$ Million)
Figure 69. Human Immunodeficiency Virus Type-1 Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232